A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients

International Journal of Gynecological Cancer

Volumn 23, Issue 5, 2013, Pages 884-889

  Coronel, Jaime Alberto ^a   Cetina, Lucely Del Carmen ^a   Cantu, David ^a   Cerezo, Oscar ^a   Hernandez, Cintia Sanchez ^a   Rivera, Lesbia ^b   Chacon, Adela Poitevin ^b   Duenas Gonzalez, Alfonso ^c  

^a Division of Clinical Research   (Mexico)

^b Department of Radiotherapy ^*  (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Aged patient; Cervical cancer; Cisplatin; Comorbidities; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CYSTITIS; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOSENSITIZATION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIATION-SENSITIZING AGENTS; UTERINE CERVICAL NEOPLASMS; VINBLASTINE;

EID: 84880424003     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182915c69     Document Type: Article

References (26)

1. Brenner BM, Meyer EW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652-659.
2. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging. 1998;13:357-379.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-1431.
4. Mensah GA. The global burden of hypertension: Good news and bad news. Cardiol Clin. 2002;20:181-185.
5. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164-176.
6. Cerasola G, Mule G, Cottone S, et al. Hypertension, microalbuminuria and renal dysfunction: The Renal Dysfunction in Hypertension (REDHY) study. J Nephrol. 2008;21:368-373.
7. Klahr S, Morrison A, Buerkert J. Effects of urinary tract obstruction on renal function. Contrib Nephrol. 1980; 23:34-46.
8. Duan SB, Wu HW, Luo JA, et al. Assessment of renal function in the early stages of nephrotoxicity induced by iodinated contrast media. Nephron. 1999;83:122-125.
9. Trimble EL, Gius D, Harlan LC. Impact of NCI Clinical Announcement upon use of chemoradiation for women with cervical cancer. J Clin Oncol. 2007;25:5537.
10. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802-5812.
11. Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678-1685.
12. Budman DR. Vinorelbine (navelbine): A third-generation vinca alkaloid. Cancer Invest. 1997;15:475-490.
13. Edelstein MP,Wolfe LA 3rd, Duch DS. Potentiation of radiation therapy by vinorelbine (navelbine) in nonYsmall cell lung cancer. Semin Oncol. 1996;23:41-47.
14. Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of the radiosensitization induced by vinorelbine in human nonYsmall cell lung cancer cells. Lung Cancer. 2001; 34:451-460.
15. Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells. Cancer Chemother Pharmacol. 2002; 49:385-390.
16. Mundt AJ, Rotmensch J, Waggoner SE, et al. Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2001;82:333-337.
17. Kunos C, Tian C, Waggoner S, et al. Retrospective analysis of concomitant cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: A gynecologic oncology group study. Int J Gynecol Cancer. 2009;19:1258-1263.
18. Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III nonYsmall cell lung cancer: Final results of an international phase II trial. J Thorac Oncol. 2008;3:994-1002.
19. Schwarzenberger P, Fariss A, Linares L, et al. Dose escalation of once weekly oral vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced nonYsmall cell lung cancer: A phase I/II study. Am J Med Sci. 2011;341:454-459.
20. Mundt AJ, Rotmensch J, Waggoner SE, et al. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004;92:801-805.
21. Kato S, Ohno T, Thephamongkhol K, et al. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys. 2010;77:751-757.
22. Cetina L, Rivera L, Hinojosa J, et al. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health. 2006;6:3.
23. Serkies K, Jassem J. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: A report on patient compliance and acute toxicity. Int J Radiat Oncol Biol Phys. 2004;60:814-821.
24. Ikushima H, Osaki K, Furutani S, et al. Chemoradiation therapy for cervical cancer: Toxicity of concurrent weekly cisplatin. Radiat Med. 2006;24:115-121.
25. Sarkar SK, Patra NB, Goswami J, et al. Comparative study of efficacy and toxicities of cisplatin vs vinorelbine as radiosensitisers in locally advanced head and neck cancer. J Laryngol Otol. 2008;122:188-192.
26. Balducci L, Carreca I. The role of myelopoietic growth factors in managing cancer in the elderly. Drugs. 2002; 62:47-63.